Levonorgestrel Intrauterine System For Emergency Contraception

Pregnancy, Unplanned Clinical Trial

— LIFE  

Official title:

Levonorgestrel Intrauterine System For Emergency Contraception: a Randomized Control Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01539720
• Other study ID #: 201201007
• Status: Completed
• Phase: N/A
• Start date: December 2012
• Est. completion date: November 30, 2018

Study information

• Verified date: January 2024
• Source: Planned Parenthood of the St. Louis Region and Southwest Missouri
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to test the levonorgestrel intrauterine system as a method for emergency contraception. Emergency contraception refers to pregnancy prevention after an act of intercourse.

While the levonorgestrel intrauterine system is approved as a contraceptive method, it is considered investigational as emergency contraception, which means that it has not been approved by the U.S. Food and Drug Administration. This study will compare the device to the most common types of emergency contraception, oral Ulipristal acetate, or oral levonorgestrel. The oral levonorgestrel regimen was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 1998. This method involves taking a 1.5mg pill of levonorgestrel in a single, one time dose. The Ulipristal acetate was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 2010. This method involves taking a 30mg pill of Ulipristal acetate in a single, one time dose.

Description:

Unintended pregnancy rates in the United States are among the highest of developed nations. These high rates can largely be attributed to incorrect or under contraception of women. One focus of decreasing unintended pregnancy and abortion rates has centered on expanding access to and use of long acting reversible contraceptive (LARC) methods which include intrauterine devices (IUDs) and subdermal implants. Emergency contraception, or post-coital contraception, offers significant reductions in the chance of pregnancy following an act of unprotected or under-protected vaginal intercourse. The most common methods of emergency contraception used in the United States are the oral levonorgestrel regimen and oral ulipristal acetate (Ella) regimen which reduce pregnancy risk by up to 89%. More effective, but rarely used, is the Cu T-380 intrauterine device (Copper IUD). The IUD has the added benefit of providing extended contraceptive use beyond the single episode of unprotected intercourse. The Cu-T380 has been associated with heavier and more crampy menses however, likely dissuading women from use. Among all IUD users, the levonorgestrel intrauterine system (LNG-IUS) has gained popularity over the Cu-T380, perhaps because it offers the potential to improve menstrual related symptoms. There is no data however on the efficacy of the LNG-IUS as a form of emergency contraception. The purpose of this study is to evaluate the efficacy of the LNG-IUS as a method of emergency contraception. Participants will be randomized to receive either the most common method, oral emergency contraception, or the LNG-IUS. Participants will then be evaluated 5-6 weeks following method allocation for pregnancy. Lastly, participants will be asked to complete a telephone surveys at 6 and 12 months following method allocation assessing their use of a consistent contraceptive method, their satisfaction with their contraceptive method, any use of emergency contraception since their enrollment in the study, and lastly any unintended pregnancies experienced since enrollment in the study. If we could show that the LNG-IUS is as effective as the most commonly prescribed method of emergency contraception, we would be introducing another opportunity for LARC initiation and subsequently impacting unintended pregnancy and abortion rates.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 274
• Est. completion date: November 30, 2018
• Est. primary completion date: November 30, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 14 Years to 45 Years

Eligibility

Inclusion Criteria:

• Women age 14-45

• Under-protected intercourse within the last five days (120 hours)

• Willingness to accept either intervention: intrauterine contraception or oral emergency contraception (EC)

• Ability and willingness to follow-up for in clinic urine pregnancy test (UPT)

• Ability and willingness to be contacted by phone for 6 and 12 month follow-up

Exclusion Criteria:

• Positive pregnancy test

• Non-English speaking

• Contraindication to intrauterine contraception or oral EC

• Inability or unwillingness to comply with follow-up

Related Conditions & MeSH terms

• Emergencies
• Pregnancy, Unplanned
• Pregnancy; Accident

Intervention

Drug:
• Ulipristal acetate
30 mg tablet

Device:
• levonorgestrel IUS
Levonorgestrel IUS, 52mg placed intrauterine

Locations

Country	Name	City	State
United States	Atlanta Women's Center	Atlanta	Georgia
United States	Indiana University School of Medicine	Indianapolis	Indiana
United States	Washington University School of Medicine in St. Louis	Saint Louis	Missouri

Sponsors (5)

Lead Sponsor	Collaborator
Planned Parenthood of the St. Louis Region and Southwest Missouri	Planned Parenthood Federation of America, University of Colorado, Denver, University of Rochester, William and Flora Hewlett Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Pregnancy Following Emergency Contraception	Observed pregnancies at 5 weeks and at 6 months in the LNG-IUD group will be compared to those in the oral UPA group.	5 weeks post-randomization
Secondary	Number of Participants Using Any LARC Method at 6 Months Post Randomization	The number of participants who reported using any type of long acting reversible contraception (LARC) use at 6 months following method allocation will be evaluated, whether or not it was their allocated LNG-IUS.	6 months post randomization
Secondary	Number of Participants Reporting Continuation and Satisfaction With Their Study Allocated LNG-IUS	Continuation and satisfaction among participants in the LNG-IUS arm who reported still using their LNG-IUS at 6 month post randomization.	6 months post randomization